Redcare Pharmacy Shares Find Footing Following Steep Decline

Redcare Pharmacy shares stabilize after hitting lows. Strong 2025 results overshadowed by lowered 2026 OTC growth and margin targets, as German giants dm and Rossmann enter the online pharmacy market.

After touching a fresh 52-week low, shares of Redcare Pharmacy are showing tentative signs of stabilization in early trading. The recent severe sell-off was triggered by disappointing margin guidance and an increasingly competitive landscape, now further intensified by the entry of two German drugstore giants into the online pharmacy sector.

Revised Outlook Sparks Investor Retreat

The company's preliminary figures for the 2025 fiscal year appeared robust at first glance. Revenue climbed 24% to €2.9 billion, while adjusted EBITDA surged 72%. Notably, prescription medication sales crossed the €1 billion threshold for the first time. Despite these results, investor sentiment turned negative due to a 2026 forecast that fell markedly short of expectations.

Management now anticipates growth of only 8% to 10% in the over-the-counter (OTC) segment, a significant reduction from the previously targeted 16%. More impactful was the downward revision of the medium-term margin target, lowered from 8% to 5%. CEO Olaf Heinrich attributed this adjustment to the slower-than-expected adoption of electronic prescriptions and mounting competitive pressures in the OTC market.

New Competitive Threats Emerge

That competitive pressure is now materializing in concrete form. At the turn of the year, dm launched its own digital pharmacy platform, "dm-med," operated from a logistics center in the Czech Republic. Competitor Rossmann is following suit. CEO Raoul Roßmann has labeled the planned online pharmacy a "central project for 2026." Notably, Rossmann will operate the service from the Netherlands, placing it directly within Redcare's home market. The Rossmann app, with approximately 11 million current users, is slated to serve as the primary access point for the new offering.

According to the German E-Commerce and Distance Selling Trade Association (Bundesverband E-Commerce und Versandhandel), the German online pharmacy market recently grew by six percent—a expanding segment that is now attracting significantly more competition.

Regulatory and Operational Counterweights

Not all developments weigh negatively on the outlook. Federal Health Minister Nina Warken has announced plans to potentially increase the fixed reimbursement per e-prescription to €9.50. Redcare emphasizes that every additional cent in the prescription (Rx) business flows almost directly to the bottom line. Furthermore, a Federal Court of Justice ruling has further opened the online market for prescription medicines.

On the operational front, a new fulfillment center in Pilsen, Czech Republic, commenced operations in December 2025. The facility is designed to increase annual shipping capacity for non-prescription items by up to 15 million packages and enable shorter delivery routes.

Data from analytics firm Hazeltree (as of March 11, 2026) indicates that institutional short sellers have reduced their short positions by more than ten percent compared to the previous month. This suggests that at least some professional market participants view the potential for further downside as limited.

Upcoming Quarterly Report as Key Catalyst

The next significant test for Redcare will arrive on May 6, 2026, when the company reports its first-quarter 2026 results. This release will provide the first clear indication of whether prescription sales momentum is being maintained, if the OTC segment is stabilizing despite new rivals, and if the revised margin guidance for 2026 remains achievable.